Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 9095 results

  1. Baloxavir marboxil for treating influenza in people 12 years and over at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment

    Awaiting development Reference number: GID-TA11735 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Doravirine-islatravir for previously untreated HIV-1 infection

    Awaiting development Reference number: GID-TA11734 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy

    Awaiting development Reference number: GID-TA11736 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. MK-3000 for treating diabetic macular oedema

    Awaiting development Reference number: GID-TA12473 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672

    In development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    In development Reference number: GID-TA11052 Expected publication date:  17 February 2027

    Technology appraisal guidance
    In development

  14. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date:  17 December 2027

    NICE guideline
    In development

  15. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573

    In development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    In development